NL-OMON38924招募中不适用
A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by a High Dosing Regimen in Subjects with Inflammatory Bowel Disease (PROMISE) - P-Monofer-IBD-02
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subjects with age >= 18 years;2. Subjects diagnosed with IBD either in remission or active ;3. Hb < 12 g/dL for women and Hb < 13 g/dL for men;4. Subjects with a CRP above upper limit of normality must have a ferritin below 100 µg/L, whereas subjects with a CRP below or equal to upper limit of normality must have a ferritin below 30 µg/L ;5. Willingness to participate after signing informed consent
排除标准
- •1. Patient judged by the physician to be in need of surgery due to Crohn's disease or ulcerative colitis within the next 2 months;2. Anaemia predominantly caused by factors other than IDA ;3. Iron overload or disturbance in utilisation of iron (e.g. haemochromatosis and haemosiderosis);4. Known hypersensitivity to any excipients of iron isomaltoside 1000;5. History of multiple allergies;6. Decompensated liver cirrhosis or active viral hepatitis (defined as Alanine Aminotransferase (ALAT) > 3 times upper limit of normal);7. Acute and/or chronic infections ;8. Body weight < 50 kg;9. Rheumatoid arthritis with symptoms or signs of active joint inflammation ;10. Pregnancy and nursing. In order to avoid pregnancy, women have to be postmenopausal, surgically sterile, or use one of the following contraceptives during the whole study period and 5 days after the study has ended (i.e. 5 times plasma biological half-life of the investigational medicinal product): intrauterine devices and hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release);11. Blood transfusion within the previous 12 weeks;12. Subjects with a history of asthma, allergic eczema, or other atopic allergy ;13. Planned elective surgery during the study;14. Untreated Vitamin B12 or folate deficiency, defined as values below the lower reference range;15. Participation in any other clinical study within 3 months prior to Screening;16. IV iron treatment within 8 weeks prior to Screening ;17. Oral iron treatment within 1 week prior to Screening;18. ESA treatment within 8 weeks prior to Screening ;19. Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study
研究者
相似试验
进行中（未招募）
不适用
A clinical Safety Study of the medicinal product Monofer given into a vein and administered by a High Dosing Regimen in patients with Inflammatory Bowel DiseaseEUCTR2011-003121-94-DKPharmacosmos A/S30
进行中（未招募）
不适用
A clinical Safety Study of the medicinal product Monofer given into a vein and administered by a High Dosing Regimen in patients with Inflammatory Bowel DiseaseEUCTR2011-003121-94-NLPharmacosmos A/S30
进行中（未招募）
不适用
A clinical Safety Study of the medicinal product Monofer given into a vein and administered by a High Dosing Regimen in patients with Inflammatory Bowel DiseaseEUCTR2011-003121-94-SEPharmacosmos A/S30
进行中（未招募）
1 期
A prospective study of the safety and efficacy of the use of a Lipiodol Emulsion for the embolization of inflammatory hypervascularizations observed in patients with articular or abarticular pain in the knee - LipioJoint 1EUCTR2020-002206-10-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)22
尚未招募
Unknown
A prospective study on the safety and efficacy of additional cryobiopsy using an ultrathin cryoprobe to ROSE(;rapid on-site cytologic evaluation) negative of forceps biopsyPeripheral pulmonary lesions which is suspected malignancyJPRN-UMIN000052642HO Okayama Medical Center60